• Conventional Antibody Drug Conjugates (ADCs) target single antigens expressed on the tumour cell surface

​

• Many of the targeted antigens are not cancer-restricted and are often widely expressed on healthy cells, resulting in debilitating on-target, off-tissue toxicities

​

• BiVictriX has identified a unique, cancer-restricted antigen fingerprint, absent from healthy cells, which can be exploited to produce truly cancer selective therapeutics

​

• The Bi-Cygni   technology was developed to exploit this concept and expedite the development of bispecific therapeutics with improved therapeutic index

​

• BiVictriX's Bi-Cygni   ADCs demonstrate superior potency and tumour selectivity compared to conventional ADCs

BiVictriX links Bi-Cygni   to expertise in the design, discovery and development of Antibody Drug Conjugates (ADCs).

®

®

®